Eugenia Girda
Eugenia Girda has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Christoph M. Ahlers
18I-Mab Biopharma, Rockville, Maryland
16 shared publications - Claire (Cong) Xu
18I-Mab Biopharma, Rockville, Maryland
16 shared publications - Farshid Dayyani
University of California Irvine 3 Division of Hematology/Oncology, Department of Medicine Orange, California
16 shared publications - Funan Liu
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China
16 shared publications - Geoffrey Yuyat Ku
Memorial Sloan Kettering Cancer Center
16 shared publications - Hongming Pan
Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
16 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Table 6. Treatment-related SAEs. By-patient listing of treatment-related SAEs, including action taken with givastomig and AE outcome.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Table 6. Treatment-related SAEs. By-patient listing of treatment-related SAEs, including action taken with givastomig and AE outcome.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Table 8. Patient listing of tumor type, givastomig dose, Claudin 18.2, and PD-L1 expression and best overall response (BOR).
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Table 8. Patient listing of tumor type, givastomig dose, Claudin 18.2, and PD-L1 expression and best overall response (BOR).
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Figure 4. Change in Soluble 4-1BB over time in solid tumors. Pharmacodynamic effect on peripheral s4-1BB at all visits (A); at cycle 1 day 15 (B).
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Figure 4. Change in Soluble 4-1BB over time in solid tumors. Pharmacodynamic effect on peripheral s4-1BB at all visits (A); at cycle 1 day 15 (B).
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Table 2. Representativeness of Study Participants.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Table 2. Representativeness of Study Participants.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Table 7. Mean pharmacokinetic parameters by givastomig dose.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Table 7. Mean pharmacokinetic parameters by givastomig dose.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Table 4. Fatal Treatment-Emergent Adverse Events (TEAE). By-patient listing of TEAEs resulting in death.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Table 4. Fatal Treatment-Emergent Adverse Events (TEAE). By-patient listing of TEAEs resulting in death.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Figure 1. Development of human CLDN18.2-dependent 4-1BB agonistic bispecific antibody (givastomig/ABL111). Givastomig/ABL111 was designed to target both CLDN18.2 and 4-1BB. N300A mutation was introduced to prevent the Fc portion from binding FcγR (A). Illustration showing the mechanism of action of givastomig/ABL111 (B). Source: Gao et al, J Immunother Cancer 2023, doi:10.1136/jitc-2023-006704.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Figure 1. Development of human CLDN18.2-dependent 4-1BB agonistic bispecific antibody (givastomig/ABL111). Givastomig/ABL111 was designed to target both CLDN18.2 and 4-1BB. N300A mutation was introduced to prevent the Fc portion from binding FcγR (A). Illustration showing the mechanism of action of givastomig/ABL111 (B). Source: Gao et al, J Immunother Cancer 2023, doi:10.1136/jitc-2023-006704.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Figure 2. Study Diagram.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Figure 2. Study Diagram.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Figure 3. Pharmacokinetic profile of Givastomig. Mean concentrations of givastomig in serum for cycle 1 at the administered doses.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Figure 3. Pharmacokinetic profile of Givastomig. Mean concentrations of givastomig in serum for cycle 1 at the administered doses.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Figure 5. Pharmacodynamics of s4-1BB in GEC. Pharmacodynamic effect on peripheral s4-1BB at cycle 1 day 15 among 29 GEC patients treated with 8 to 15 mg/kg Q2W of givastomig. stratified by best overall response (A) and CLDN18.2 status at baseline (B).
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Supplementary Figure 5. Pharmacodynamics of s4-1BB in GEC. Pharmacodynamic effect on peripheral s4-1BB at cycle 1 day 15 among 29 GEC patients treated with 8 to 15 mg/kg Q2W of givastomig. stratified by best overall response (A) and CLDN18.2 status at baseline (B).